Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Russia
2018131377
Filed on 2017-02-14
2018131377
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Mexico
2018009867
Filed on 2017-02-14
2018009867
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Morocco
17753704.0
Filed on 2017-02-14
17753704.0
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
South Korea
2018-7024215
Filed on 2017-02-14
2018-7024215
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Japan
2021-064539
Filed on 2017-02-14
2021-064539
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
European Patent
17753704.0
Filed on 2017-02-14
17753704.0
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
China
201780011505
Filed on 2017-02-14
201780011505
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Canada
3014674
Filed on 2017-02-14
3014674
Filed on 2017-02-14
Intermittent Dosing Of Cediranib Alone Or In Combination With Durvalumab
Australia
2017221268
Filed on 2017-02-14
2017221268
Filed on 2017-02-14
Chimeric Antigen Receptors Containing Glypican 2 Binding Domains
European Patent
20751027.2
Filed on 2020-07-17
20751027.2
Filed on 2020-07-17